Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration

Danilo Iannetta,1 Michele De Maria,1 Elena Bolletta,2 Valentina Mastrofilippo,1 Antonio Moramarco,1 Luigi Fontana1 1Ophthalmology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyCorrespondence: Danilo Ia...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Iannetta D, De Maria M, Bolletta E, Mastrofilippo V, Moramarco A, Fontana L
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/e7226a4b7f9b4d9896e38281933137dd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e7226a4b7f9b4d9896e38281933137dd
record_format dspace
spelling oai:doaj.org-article:e7226a4b7f9b4d9896e38281933137dd2021-12-02T18:52:12ZSubretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration1177-5483https://doaj.org/article/e7226a4b7f9b4d9896e38281933137dd2021-08-01T00:00:00Zhttps://www.dovepress.com/subretinal-injection-of-recombinant-tissue-plasminogen-activator-and-g-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Danilo Iannetta,1 Michele De Maria,1 Elena Bolletta,2 Valentina Mastrofilippo,1 Antonio Moramarco,1 Luigi Fontana1 1Ophthalmology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyCorrespondence: Danilo IannettaOphthalmology Unit, AUSL-IRCCS Reggio Emilia, Viale Risorgimento 80, Reggio Emilia, ItalyTel +39 0522296520Fax +39 0522295839Email iannettadanilo@gmail.comPurpose: To analyse the efficacy of subretinal injection of recombinant tissue plasminogen activator (rtPA) and gas tamponade for the displacement of submacular haemorrhage (SMH).Methods: This single-centre, retrospective, case series included 25 consecutive patients (25 eyes) who underwent pars plana vitrectomy (PPV) with subretinal rtPA injection and 20% sulphur hexafluoride (SF6) tamponade. The primary outcome was SMH displacement rate, defined as the absence of subretinal blood within (complete) or outside (partial) 1500 μm centred on the fovea one month after PPV. Secondary outcomes were final best-corrected visual acuity (BCVA), central macular thickness (CMT), recurrence probability, number of anti-vascular endothelial growth factor (VEGF) injections after PPV, and intra- and post-operative complications.Results: Successful displacement was obtained in all 25 eyes (100%), with complete and partial displacement obtained in 15 (60%) and 10 (40%), respectively. BCVA significantly improved from 1.81± 0.33 to 1.37± 0.52 LogMar at 12 months from surgery (p = 0.001). The bivariate correlation analysis revealed that earlier the surgery had better visual prognosis at the end of the follow-up (p = 0.007). CMT significantly decreased from 922 ± 273.69 μm at baseline to 403.53 ± 314.64 μm at 12 months follow-up (p < 0.001). SMH recurrence was observed in two (8%) patients with a mean survival time of 11.6 ± 0.339 months and a cumulative survival probability of 88% at the end of follow-up. After PPV, the mean number of anti-VEGF injections was 3.00 ± 0.957 with no correlation with final visual acuity (p = 0.365). No intraoperative complications were recorded. Only one patient developed open funnel retinal detachment 40 days after primary PPV.Conclusion: PPV with rtPA subretinal injection and SF6 tamponade is a safe and effective technique in displacing acute SMHs secondary to neovascular AMD. It is recommended to perform within 14 days from the onset of the symptoms to achieve BCVA improvement at 12 months and proper imaging to plan future anti-VEG treatment.Keywords: macular degeneration, submacular haemorrhage, recombinant tissue plasminogen activator, pars plana vitrectomy, subretinal injectionIannetta DDe Maria MBolletta EMastrofilippo VMoramarco AFontana LDove Medical Pressarticlemacular degenerationsubmacular haemorrhagerecombinant tissue plasminogen activatorpars plana vitrectomysubretinal injectionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3649-3659 (2021)
institution DOAJ
collection DOAJ
language EN
topic macular degeneration
submacular haemorrhage
recombinant tissue plasminogen activator
pars plana vitrectomy
subretinal injection
Ophthalmology
RE1-994
spellingShingle macular degeneration
submacular haemorrhage
recombinant tissue plasminogen activator
pars plana vitrectomy
subretinal injection
Ophthalmology
RE1-994
Iannetta D
De Maria M
Bolletta E
Mastrofilippo V
Moramarco A
Fontana L
Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
description Danilo Iannetta,1 Michele De Maria,1 Elena Bolletta,2 Valentina Mastrofilippo,1 Antonio Moramarco,1 Luigi Fontana1 1Ophthalmology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyCorrespondence: Danilo IannettaOphthalmology Unit, AUSL-IRCCS Reggio Emilia, Viale Risorgimento 80, Reggio Emilia, ItalyTel +39 0522296520Fax +39 0522295839Email iannettadanilo@gmail.comPurpose: To analyse the efficacy of subretinal injection of recombinant tissue plasminogen activator (rtPA) and gas tamponade for the displacement of submacular haemorrhage (SMH).Methods: This single-centre, retrospective, case series included 25 consecutive patients (25 eyes) who underwent pars plana vitrectomy (PPV) with subretinal rtPA injection and 20% sulphur hexafluoride (SF6) tamponade. The primary outcome was SMH displacement rate, defined as the absence of subretinal blood within (complete) or outside (partial) 1500 μm centred on the fovea one month after PPV. Secondary outcomes were final best-corrected visual acuity (BCVA), central macular thickness (CMT), recurrence probability, number of anti-vascular endothelial growth factor (VEGF) injections after PPV, and intra- and post-operative complications.Results: Successful displacement was obtained in all 25 eyes (100%), with complete and partial displacement obtained in 15 (60%) and 10 (40%), respectively. BCVA significantly improved from 1.81± 0.33 to 1.37± 0.52 LogMar at 12 months from surgery (p = 0.001). The bivariate correlation analysis revealed that earlier the surgery had better visual prognosis at the end of the follow-up (p = 0.007). CMT significantly decreased from 922 ± 273.69 μm at baseline to 403.53 ± 314.64 μm at 12 months follow-up (p < 0.001). SMH recurrence was observed in two (8%) patients with a mean survival time of 11.6 ± 0.339 months and a cumulative survival probability of 88% at the end of follow-up. After PPV, the mean number of anti-VEGF injections was 3.00 ± 0.957 with no correlation with final visual acuity (p = 0.365). No intraoperative complications were recorded. Only one patient developed open funnel retinal detachment 40 days after primary PPV.Conclusion: PPV with rtPA subretinal injection and SF6 tamponade is a safe and effective technique in displacing acute SMHs secondary to neovascular AMD. It is recommended to perform within 14 days from the onset of the symptoms to achieve BCVA improvement at 12 months and proper imaging to plan future anti-VEG treatment.Keywords: macular degeneration, submacular haemorrhage, recombinant tissue plasminogen activator, pars plana vitrectomy, subretinal injection
format article
author Iannetta D
De Maria M
Bolletta E
Mastrofilippo V
Moramarco A
Fontana L
author_facet Iannetta D
De Maria M
Bolletta E
Mastrofilippo V
Moramarco A
Fontana L
author_sort Iannetta D
title Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
title_short Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
title_full Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
title_fullStr Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
title_full_unstemmed Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
title_sort subretinal injection of recombinant tissue plasminogen activator and gas tamponade to displace acute submacular haemorrhages secondary to age-related macular degeneration
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/e7226a4b7f9b4d9896e38281933137dd
work_keys_str_mv AT iannettad subretinalinjectionofrecombinanttissueplasminogenactivatorandgastamponadetodisplaceacutesubmacularhaemorrhagessecondarytoagerelatedmaculardegeneration
AT demariam subretinalinjectionofrecombinanttissueplasminogenactivatorandgastamponadetodisplaceacutesubmacularhaemorrhagessecondarytoagerelatedmaculardegeneration
AT bollettae subretinalinjectionofrecombinanttissueplasminogenactivatorandgastamponadetodisplaceacutesubmacularhaemorrhagessecondarytoagerelatedmaculardegeneration
AT mastrofilippov subretinalinjectionofrecombinanttissueplasminogenactivatorandgastamponadetodisplaceacutesubmacularhaemorrhagessecondarytoagerelatedmaculardegeneration
AT moramarcoa subretinalinjectionofrecombinanttissueplasminogenactivatorandgastamponadetodisplaceacutesubmacularhaemorrhagessecondarytoagerelatedmaculardegeneration
AT fontanal subretinalinjectionofrecombinanttissueplasminogenactivatorandgastamponadetodisplaceacutesubmacularhaemorrhagessecondarytoagerelatedmaculardegeneration
_version_ 1718377419085185024